UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

(RULE 14a-101)

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934 (Amendment No. ___)

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☒ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material Pursuant to § 240.14a-12

VASCULAR SOLUTIONS, INC.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:  ______________________

(2) Aggregate number of securities to which transaction applies:  _____________________

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):  _______________

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

☐ Fee paid previously with preliminary materials.

☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.  Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:  ________________________

(2) Form, Schedule or Registration Statement No.:  ________________________

(3) Filing Party:  ________________________

(4) Date Filed:  ________________________

Dear Fellow Shareholder:

You are cordially invited to attend the 2016 annual meeting of shareholders of Vascular Solutions, Inc., which will be held at the Crowne Plaza Hotel Minneapolis West, 3131 Campus Drive, Plymouth, Minnesota beginning at 1:30 p.m. on Friday, April 29, 2016.

This booklet contains your official notice of the 2016 annual meeting of shareholders and a proxy statement that includes information about matters to be acted upon at the annual meeting.  Officers and directors of Vascular Solutions, Inc. will be at the meeting to review the company’s operations and to answer questions and discuss matters that may properly arise.

Whether or not you plan to attend the annual meeting, please complete, sign, date and mail the enclosed proxy card promptly.  If you attend the annual meeting, you may revoke your proxy and vote in person if you wish, even if you have previously returned your proxy card.

I sincerely hope that you will be able to attend our annual meeting to review the past year and our future plans.

Sincerely,

Howard C. Root

Chief Executive Officer

March 25, 2016

VASCULAR SOLUTIONS, INC.

6464 Sycamore Court North

Minneapolis, Minnesota 55369

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS

TO BE HELD APRIL 29, 2016

The 2016 annual meeting of the shareholders of Vascular Solutions, Inc., a Minnesota corporation, will be held at the Crowne Plaza Hotel Minneapolis West, 3131 Campus Drive, Plymouth, Minnesota, beginning at 1:30 p.m. on Friday, April 29, 2016 for the following purposes:

1.     To elect seven directors to serve on the Board of Directors for a term of one year and until their successors are duly elected and qualified.

2.     To ratify the appointment of Baker Tilly Virchow Krause, LLP as our independent registered public accounting firm for the year ending December 31, 2016.

3.     To transact such other business as may properly come before the meeting or any adjournment thereof.

The Board of Directors recommends that an affirmative vote be cast FOR all of the director nominees and FOR ratification of the independent registered public accounting firm.

Only holders of record of common stock at the close of business on March 7, 2016 will be entitled to notice of and to vote at the annual meeting or any adjournment thereof.  It is important that your shares of common stock be represented at the annual meeting.  You are urged to complete, sign and date the accompanying proxy card, which is solicited by the Board of Directors of Vascular Solutions, and mail it promptly in the enclosed envelope.  Your proxy will not be used if you attend the annual meeting and vote in person.  If you wish to attend the meeting to vote in person and need directions, please contact Vascular Solutions’ investor relations at 763.656.4300 or investorrelations@vasc.com.

By Order of the Board of Directors

Gordon Weber

Secretary

March 25, 2016

IMPORTANT:  PLEASE RETURN EACH PROXY CARD SENT TO YOU.

PROXY STATEMENT

TABLE OF CONTENTS

	Page
INFORMATION ABOUT THE ANNUAL MEETING AND VOTING	1
Record Date; Shareholders Entitled to Vote; Quorum	1
Voting Your Shares	1
Changing Your Vote by Revoking Your Proxy	1
How Proxies Are Counted	1
Cost of Solicitation	2
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT	2
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE	3
PROPOSAL 1: ELECTION OF DIRECTORS	3
CORPORATE GOVERNANCE	6
Board Leadership Structure	6
Board Independence	6
Meetings Attendance	7
Board Committees	7
Director Selection and Qualifications	9
Communications with the Board	9
Risk Oversight by the Board of Directors	9
DIRECTOR COMPENSATION	10
RELATED PERSON TRANSACTION POLICY AND RELATED PERSON TRANSACTIONS	12
Related Person Transaction Policy	12
Related Person Transactions	12
EXECUTIVE COMPENSATION	12
Compensation Discussion and Analysis	12
Compensation Committee Report	20
Summary Compensation Table	21
Grants of Plan-Based Awards for Fiscal 2015	22
Outstanding Equity Awards at 2015 Fiscal Year-End	23
Option Exercises and Stock Vested for Fiscal 2015	24
Employment Agreements, Separation Agreements, Termination and Potential Change in Control Payments	24
REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS	27
PROPOSAL 2: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	28
ADDITIONAL INFORMATION ABOUT OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	28
Audit Fees	28
Audit-Related Fees	28

i

Tax Fees	28
All Other Fees	28
Pre-Approval Policies and Procedures	28
ANNUAL REPORT ON FORM 10-K	29
“HOUSEHOLDING” OF PROXY MATERIALS	29
OTHER MATTERS	29
PROPOSALS FOR THE NEXT ANNUAL MEETING	29

ii

PROXY STATEMENT

This proxy statement is provided in connection with the 2016 annual meeting of shareholders of Vascular Solutions, Inc. and any adjournment or postponement of the meeting.  The accompanying proxy is solicited by our Board of Directors.  This proxy statement and the accompanying form of proxy are first being sent or given to shareholders on or about March 25, 2016.

INFORMATION ABOUT THE ANNUAL MEETING AND VOTING

Record Date; Shareholders Entitled to Vote; Quorum

Holders of record of the shares of our common stock at the close of business on March 7, 2016 will be entitled to vote on all matters at the annual meeting.  Each share of common stock will be entitled to one vote, and there is no cumulative voting.  On March 7, 2016, a total of 17,401,226 shares of common stock were outstanding.  A majority of the voting power of the outstanding shares of common stock entitled to vote, represented in person or by proxy, will be required to constitute a quorum for the annual meeting.

Voting Your Shares

Our Board of Directors is soliciting proxies from our shareholders.  By completing and returning the accompanying proxy, you will be authorizing Howard Root and Gordon Weber to vote your shares.  If your proxy is properly signed and dated, it will be voted as you direct.  If you attend the annual meeting in person, you may vote your shares by completing a ballot at the meeting.

Changing Your Vote by Revoking Your Proxy

Your proxy may be revoked at any time before it is voted at the annual meeting by (1) giving notice of revocation, in writing, to our Corporate Secretary at the address shown on page 29 of this proxy statement so that it is received by April 28, 2016, (2) execution of a later dated proxy, or (3) attending and voting at the annual meeting.

How Proxies Are Counted

If you return a signed and dated proxy card but do not indicate how the shares are to be voted, those shares will be voted FOR each of the director nominees and FOR ratification of the independent registered public accounting firm.  Votes cast by proxy or in person at the annual meeting will be tabulated by the election inspectors appointed for the annual meeting.

Shares voted as abstentions on any matter (or a “withhold vote for” as to directors) will be counted for purposes of determining the presence of a quorum at the annual meeting and treated as unvoted, although present and entitled to vote, for purposes of determining the approval of each matter as to which a shareholder has abstained.  Abstentions will have no effect on the election of directors, but will have the same effect as a vote “against” the other proposal.

Broker “non-votes” will be counted for purposes of determining the presence of a quorum at the annual meeting, however, broker “non-votes” on any matter will not be considered as present and entitled to vote for purposes of determining the approval of such matter.  Under the rules of the New York Stock Exchange, brokers do not have discretionary authority to vote with respect to the election of directors.

Our Board of Directors knows of no matters to be presented for action at the annual meeting other than those set forth herein.  If any other matters properly come before the annual meeting, however, the persons named in the proxy will vote on such other matters and/or for other nominees in accordance with their best judgment.  This includes a motion to adjourn or postpone the annual meeting to solicit additional proxies.

Cost of Solicitation

All expenses in connection with this solicitation will be paid by Vascular Solutions, Inc.  Our officers, directors and regular employees, who will receive no extra compensation for their services, may solicit proxies by telephone or electronic transmission.

Important Notice Regarding the Availability of Proxy Materials for the

Annual Meeting of Shareholders to be held on April 29, 2016:

This Proxy Statement and our 2015 Annual Report are available at www.vasc.com.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information with respect to the beneficial ownership of our common stock as of February 26, 2016 by each person, or group of affiliated persons, who is known by us to own beneficially more than 5% of our common stock, each of our directors, each of our executive officers named in the Summary Compensation Table below and all of our directors and executive officers as a group.

Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission (the “SEC”).  In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock under options held by that person that are currently exercisable or exercisable within 60 days of February 26, 2016 are considered outstanding.  These shares, however, are not considered outstanding when computing the percentage ownership of each other person.  The number of shares subject to options that each beneficial owner has the right to acquire within 60 days of February 26, 2016 is described in the footnotes to the table.

Except as indicated in the footnotes to this table, each shareholder named in the table has sole voting and investment power for the shares shown as beneficially owned by them, and the shares beneficially owned by our directors and executive officers are not subject to any pledge.  Percentage of ownership is based on 17,401,226  shares of common stock outstanding on February 26, 2016.

Name of Beneficial Owner	Amount and Nature of Beneficial Ownership(1)			Percent of Class
Directors and executive officers
Howard Root		711,340			4.0%
Richard Nigon		124,808			*
Charmaine Sutton		72,717			*
Jorge Saucedo		59,320			*
Chad Kugler		56,872			*
James Hennen		44,217			*
John Erb		40,306			*
Martin Emerson		37,008			*
Carrie Powers		35,722			*
Richard Kramp		8,483			*
Paul O’Connell		4,737			*
All directors and executive officers as a group (13 persons)		1,237,430	(2)		6.9%

2

Name of Beneficial Owner	Amount and Nature of Beneficial Ownership(1)			Percent of Class
Other beneficial owners:
BlackRock, Inc.		1,572,240	(3)		9.0%
55 East 52nd Street
New York, New York  10055
Wellington Management Group LLP		1,118,828	(4)		6.4%
c/o Wellington Management Company LLP
280 Congress Street
Boston, Massachusetts  02210

* Less than 1%

(1) Includes the following shares subject to options exercisable within 60 days after February 26, 2016:

Name	Shares		Name	Shares		Name	Shares
Mr. Root		360,000	Mr. Saucedo		40,000	Mr. Emerson		30,000
Mr. Nigon		60,000	Mr. Erb		30,000

(2) Includes 520,000 shares subject to options exercisable within 60 days after February 26, 2016.

(3) The number of shares indicated is based on information reported to the SEC in a Schedule 13G filed by BlackRock, Inc. on January 28, 2016 and reflects beneficial ownership as of December 31, 2015.  BlackRock, Inc. reports having sole dispositive power with respect to these shares and sole voting power with respect to 1,534,594 of these shares.

(4) The number of shares indicated is based on information reported to the SEC in a Schedule 13G filed by Wellington Management Group LLP on February 11, 2016 and reflects beneficial ownership as of December 31, 2015.  Wellington Management Company, LLP reports having shared dispositive power with respect to these shares and shared voting power with respect to 953,696 of these shares.

SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), requires our executive officers and directors and persons who beneficially own more than 10% of our common stock to file initial reports of ownership and reports of changes in ownership with the SEC.  Such executive officers, directors and greater than 10% beneficial owners are required by the regulations of the SEC to furnish us with copies of all Section 16(a) reports they file.

Based solely on a review of the copies of such reports furnished to us and written representations from the executive officers and directors, we believe that all Section 16(a) filing requirements applicable to our executive officers and directors and greater than 10% beneficial owners have been timely met.

PROPOSAL 1:

ELECTION OF DIRECTORS

Our Board of Directors currently has seven members, all of whom have been nominated for election to our Board of Directors at the 2016 annual meeting of shareholders to hold office for a term of one year and until their successors are duly elected and qualified (except in the case of earlier death, resignation or removal).  In the unlikely event that the nominees are unable to stand for election at the annual meeting, the persons named as proxies will vote for such other persons as the Board of Directors or proxies may designate.

Information regarding the nominees to the Board of Directors is set forth below.

3

John Erb, age 67, has served as our Chairman of the Board since May 2011 and has been on our Board of Directors since October 2002.  Mr. Erb has over 40 years of experience in the medical device industry.  Mr. Erb is currently Chief Executive Officer and Chairman of Sunshine Heart, Inc., a publicly traded medical device company developing new devices for the treatment of heart disease.  Mr. Erb has been Chairman of Sunshine Heart since October 2012 and Chief Executive Officer since March 2016.  Mr. Erb is co-founder of NuAx, Inc., a medical device company involved in developing new devices for the treatment of heart disease since February 2007.  During 2007, Mr. Erb served as Executive Chairman of the board of directors of CHF Solutions, Inc., a medical device company involved in the development, manufacturing and distribution of devices to treat congestive heart failure.  From 2001 through 2006, Mr. Erb was Chief Executive Officer of CHF Solutions, Inc.  Mr. Erb was President and Chief Executive Officer of IntraTherapeutics, Inc., a medical device company involved in the development, manufacturing and distribution of peripheral vascular stents, from 1997 until it was acquired by Sulzer Medica in 2001.  Previously, Mr. Erb was Vice President of Worldwide Operations for Schneider Worldwide, a division of Pfizer, Inc.  Mr. Erb served as a director of SenoRx, Inc., a publicly traded company, from December 2001 until it was acquired by C. R. Bard, Inc. in July 2010, and also served as a director of CryoCath Technologies Inc., a publicly traded Canadian company, from October 2000 until it was acquired in December 2008.  Mr. Erb currently serves as a director of Sunshine Heart, Inc. and Osprey Medical, Inc., as well as a director of several private companies.  With over 30 years of experience in the medical device industry, including 15 years of experience serving as Chief Executive Officer of medical device companies, Mr. Erb brings to our Board valuable business, management and leadership experience and a deep understanding of the challenges presented in growing a medical device company.  In addition, his role on the boards of SenoRx, Inc. and CryoCath Technologies Inc. has provided him with public company board experience.  Through his position managing significant operations of a multi-national medical device company, Mr. Erb also brings to the Board valuable private company operational experience.

Richard Nigon, age 68, has served on our Board of Directors since November 2000.  Mr. Nigon is currently Senior Vice President of Cedar Point Capital, Inc., a private company that raises capital for early stage companies, where he has served since 2007.  From February 2001 until December 2006, Mr. Nigon was a Director of Equity Corporate Finance for Miller Johnson Steichen Kinnard (“MJSK”), a privately held investment firm.  In December 2006, MJSK was acquired by Stifel Nicolaus and Mr. Nigon became a Managing Director of Private Placements until May 2007.  From February 2000 to February 2001, Mr. Nigon served as the Chief Financial Officer of Dantis, Inc., a web hosting company.  Prior to joining Dantis, Mr. Nigon was employed by Ernst & Young, LLP from 1970 to 2000, where he served as partner from 1981 to 2000.  While at Ernst & Young, LLP, Mr. Nigon served as the Director of Ernst & Young’s Twin Cities Entrepreneurial Services Group and was the coordinating partner on several publicly traded companies in the consumer retailing and manufacturing sectors.  Mr. Nigon currently serves as a director of Northern Technologies International Corporation and served on the board of directors of Virtual Radiologic Corporation from May 2007 until it was acquired in July 2010.  Mr. Nigon also serves as a director of several private companies.  Through his 30 years of service at Ernst & Young, LLP, Mr. Nigon brings to our Board extensive public accounting and auditing experience, including particular experience with emerging growth companies.  Mr. Nigon also brings to the Board a strong background in financial controls and reporting, financial management, financial analysis, SEC reporting requirements and mergers and acquisitions.Mr. Nigon’s strategic planning expertise gained through his management and leadership roles at private investment firms also makes him well-suited to serve as a member of our Board of Directors.

Paul O’Connell, age 63, has served on our Board of Directors since January 2002.  In January of 2014, Mr. O’Connell became President of B. Braun CeGaT, a genomic sequencing and diagnostic company providing services to clinicians and hospitals in the United States.  Since 2001, Mr. O’Connell has also been serving as President of B. Braun Interventional Systems, Inc., a wholly owned subsidiary of B. Braun Melsungen AG, a global supplier of products for anesthesia, intensive medicine, cardiology, extra corporeal blood treatment and surgery as well as services for hospitals, general practitioners and the homecare sector.  Mr. O’Connell was previously Vice President of the Vascular Interventional Products Group of B. Braun Medical, an international medical device company, from 1989 to 2001.  In addition, from 1999 through 2001, Mr. O’Connell provided marketing and technical support consulting services to medical device companies.  Mr. O’Connell was the owner of Sablier, a medical device company, from 1998 through 1999, where he developed new technologies for the treatment of thromboembolic diseases and for distal protection during carotid endarterectomy.  From 1993 through 1998, Mr. O’Connell was Vice President and General Manager of the Vena Tech division of B. Braun Medical, a medical device business he originally co-founded in 1988 and sold to B. Braun Medical in 1993.  Through more than 20 years of experience as the General Manager or President of growth-oriented medical device companies within cardiology and radiology fields of practice, Mr. O’Connell brings to our Board management and operational experience and valuable clinical experience related to our product focus areas.

4

Howard Root, age 55, has served as our Chief Executive Officer and a member of our Board of Directors since he co-founded Vascular Solutions in February 1997.  From 1990 to 1995, Mr. Root was employed by ATS Medical, Inc., a mechanical heart valve company, most recently as Vice President and General Counsel.  Prior to joining ATS Medical, Mr. Root practiced corporate law at the law firm of Dorsey & Whitney LLP for over five years, specializing in representing emerging growth companies.  As our Chief Executive Officer and a member of our Board of Directors since co-founding Vascular Solutions in 1997, and with over 20 years of experience in the medical device industry, Mr. Root brings to our Board a deep knowledge of Vascular Solutions, its operations and the medical device industry.  Through his prior legal practice, Mr. Root gained familiarity with a broad range of legal, regulatory, compliance and other corporate governance issues valuable to our Board of Directors.  Mr. Root also provides to the Board management’s views and perspectives on various matters.

Jorge Saucedo, age 52, has served on our Board of Directors since April 2006.  Dr. Saucedo is Division Head, Division of Cardiology and Co-Director of the Cardiovascular Institute at NorthShore University HealthSystem, where he has served since June of 2013.  Prior to that, Dr. Saucedo was Professor of Medicine, Vice Chief, Clinical Affairs, Cardiovascular Section, and Director, Cardiac Catheterization Laboratories at the University of Oklahoma Health Sciences Center, where he served from 2002 to 2013.  Previously, from 1998 to 2002, Dr. Saucedo was Assistant Professor of Internal Medicine, and Director, Catheterization Laboratories at the University of Arkansas for Medical Sciences.  Dr. Saucedo’s post-graduate work includes fellowships in interventional cardiology at Washington Hospital Center in Washington, D.C. and the University of Michigan Hospitals, Ann Arbor as well as a cardiology fellowship at Instituto Nacional de Cardiologia “Ignacio Chávez,” Mexico City, Mexico.  Dr. Saucedo is board certified in internal medicine, cardiovascular diseases and interventional cardiology.  In addition, Dr. Saucedo received a Master of Business Administration degree from University of Arkansas at Little Rock.  Dr. Saucedo’s education, training and experience as an interventional cardiologist, which is the primary clinical user of our products, make him well-suited to serve as a member of our Board of Directors.

Martin Emerson, age 52, has served on our Board of Directors since May 2010.  Mr. Emerson has served as President and Chief Executive Officer and director of Galil Medical, a medical device company focused on cryotherapy treatments, since April 2008.  He was the President and Chief Executive Officer and a director of American Medical Systems Holdings, Inc., a medical device company, from 2005 to January 2008, where he also served as the President and Chief Operating Officer from 2004 to 2005, the Executive Vice President of Global Sales and Marketing and Chief Operating Officer from 2003 to 2004, and the Vice President and the General Manager of International from 2000 to 2002.  Mr. Emerson has over 22 years of experience in the medical device industry.  He was the General Manager and Finance Director in Singapore for Boston Scientific Corporation from 1998 to 2000.  Mr. Emerson was the Vice President and Regional Financial Officer in Singapore for MasterCard International Incorporated from 1997 to 1998.  He also held management positions with Baxter International Inc. from 1985 to 1997, most recently as the Vice President of Finance of its European Hospital Business division in Brussels, Belgium.  Mr. Emerson is also a director of Incisive Surgical and Tepha Medical Devices, both private companies, and was a director of Wright Medical, a publicly held medical device company, from April 2006 to October 2015.  Through over 22 years of experience in the medical device industry, including service as Chief Executive Officer of public and private medical device companies, Mr. Emerson brings to our Board valuable business, management and leadership experience. Through his positions at American Medical Systems Holdings, Inc., Mr. Emerson also brings to our Board extensive expertise and insight in the areas of public company operations, domestic and international medical device marketing and sales and international business.  Mr. Emerson’s finance experience and service on two other public company boards also make him well-suited to serve as a member of our Board of Directors.

5

Richard Kramp, age 70, has served on our Board of Directors since May 2013.  Most recently, Mr. Kramp was the Chief Executive Officer and a director of Synovis Life Technologies, Inc., a diversified medical device company, from January 2007 to February 2012, when Synovis was purchased by Baxter International, Inc.  Mr. Kramp served as President of Synovis from June 2006 to January 2007, and from August 2004 to May 2006, he served as President and Chief Operating Officer of the former interventional business unit of Synovis.  Prior to joining Synovis, Mr. Kramp served as the Chief Operating Officer of Medical CV, Inc., a medical device company, and before that, as its Vice President of New Product Development.  From 1988 to 2003, Mr. Kramp served as President and Chief Operating Officer, and then President, Chief Executive Officer and a director of ATS Medical, Inc.  From 1978 to 1988, Mr. Kramp held sales and marketing positions at St. Jude Medical, Inc., serving as Vice President of Sales and Marketing from 1981 to 1988.  From 1972 to 1978, Mr. Kramp held the positions of Design Engineer, Supervisor of Electrical Design with Cardiac Pacemakers, Inc. and Territory Manager, then State Sales Manager, with a company serving as an independent representative of Cardiac Pacemakers, Inc.  Mr. Kramp currently serves as a director of NVE Corporation, a publicly held technology company, and on the board of AUM Cardiovascular, a private, early stage medical device company.  Mr. Kramp served on the board of Rochester Medical Corporation, a publicly held medical device company, from January 2013 until its acquisition by C.R. Bard in November of 2013.  Through his experience as a Chief Executive Officer with Synovis and ATS Medical, Mr. Kramp brings to the Board valuable management and operational experience in the medical device industry. Mr. Kramp’s engineering and sales and marketing experience in the industry also make him a valuable member of our Board.

OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” EACH OF THE NOMINEES.

In accordance with Minnesota law, the nominees for election as directors at the 2016 annual meeting will be elected by a plurality of the votes cast at the meeting.  This means that since shareholders will be electing seven directors, the seven nominees receiving the highest number of votes will be elected.  The number of votes withheld from one or more director nominees will have no effect on the election of any director who is among the seven nominees receiving the highest number of votes FOR his or her election.  Proxies will be voted FOR the nominees unless otherwise specified.

CORPORATE GOVERNANCE

Board Leadership Structure

In April 2011, the Board of Directors created a new position of non-executive Chairman of the Board and elected John Erb to this position, effective May 1, 2011.  The Chairman of the Board also serves as Chairman of the Compensation Committee and Chairman of the Compliance and Governance Committee, and, until December 5, 2014, served as our Compliance Officer.  The Board created the Chairman of the Board position to enhance the Board’s oversight and other responsibilities commensurate with our growth, and to provide the Chief Executive Officer with an additional resource to assist in carrying out corporate governance activities and promote adherence to our Code of Business Ethics and Conduct.

The Chairman of the Board of Directors is responsible for leading the Board and providing management and direction to the effective performance of the Board’s responsibilities.  The Chairman of the Board acts in a participatory and advisory capacity to the Chief Executive Officer in both external and internal operations, with particular assistance on the evaluation and integration of Vascular Solutions’ strategic opportunities, recruitment of management and other functional areas as our needs arise, upon the request of the Chief Executive Officer.  The Chairman would also serve as the interim successor in the event of the incapacity of the Chief Executive Officer.

Board Independence

The Board of Directors has determined that all of the current members of the Board are “independent” directors under the listing standards of the NASDAQ Stock Market LLC (“NASDAQ”), other than Mr. Root.  Mr. Root is not independent because he is employed by Vascular Solutions as our Chief Executive Officer.

6

In assessing the independence of our directors in 2015, our Board of Directors carefully considered all of the transactions, relationships and arrangements between Vascular Solutions and our independent directors or their affiliated companies.  This review was based primarily on responses of the directors to questions in a director and officer questionnaire regarding employment, business, familial, compensation and other relationships with Vascular Solutions and our management.  In assessing director independence, the Board of Directors considered our multi-year contract with B. Braun Medical, Inc. for the purchase of D-Stat Dry hemostatic bandages.  One of our directors, Mr. Paul O’Connell, is the president of a subsidiary of B. Braun Medical.  B. Braun Medical is a large, multinational medical products company with over 5,000 employees worldwide.  In fiscal 2015, 2014, and 2013, Vascular Solutions sold $311,000, $311,000, and $361,000, respectively, of product to B. Braun Medical.  The Board determined that this relationship did not impair Mr. O’Connell’s independence because his indirect interest in this transaction between Vascular Solutions and B. Braun was not material, and the amounts involved were immaterial to Vascular Solutions and the B. Braun Medical subsidiary when compared to their annual gross revenues.  In assessing director independence, the Board of Directors also considered the familial relationship between Richard Nigon and Matthew Nigon, his adult son and an employee of Vascular Solutions.  Matthew Nigon is an Account Manager for Vascular Solutions and earned aggregate compensation during 2015 of $167,000.  The Board determined that this relationship did not impair Richard Nigon’s independence because his indirect interest in the relationship between Vascular Solutions and Matthew Nigon was not material, and the amounts involved were immaterial to Vascular Solutions when compared to total compensation expense for 2015.  The Board determined that there was no transaction, relationship or arrangement between Vascular Solutions and our independent directors or the independent directors’ affiliated companies which could influence the director’s impartial judgment as a director of Vascular Solutions.

Meetings Attendance

Each of our directors is expected to make a reasonable effort to attend all meetings of the Board, applicable committee meetings and our annual meeting of shareholders.  During 2015, the Board of Directors held five meetings.  During 2015, each current director attended at least 75% of the total number of meetings of the Board of Directors and committees of the Board on which they served.  All of our directors attended our 2015 annual meeting of shareholders.

Board Committees

The Board of Directors has Compliance and Governance, Audit, and Compensation Committees, which are described below.  Each of the committees has adopted and operates under a written charter.  The charters can be found on our website at www.vasc.com by clicking under “Investor Relations.”  The following table provides membership information for each of our Board committees as of the date hereof.

Name	Compliance and Governance Committee		Audit Committee		Compensation Committee
John Erb		C				C
Martin Emerson						M
Richard Kramp		M
Richard Nigon				C
Paul O’Connell		M		M
Howard Root
Jorge Saucedo				M		M

C = Committee Chair                    M = Committee Member

Compliance and Governance Committee

The Compliance and Governance Committee’s responsibilities include, among other things:

· overseeing all Code of Conduct matters, compliance with federal healthcare program requirements and other compliance issues as they arise and recommending any proposed corrective actions related to compliance matters to the Board for approval;

· meeting quarterly with the Compliance Officer and receiving reports from the Compliance Officer regarding the effectiveness of our compliance programs and our compliance related activities;

· annually reviewing the Code of Conduct and our compliance activities and recommending any proposed changes to the Board for approval;

7

· recommending to the Board a slate of director candidates for election by shareholders at each annual meeting of shareholders and nominees for any Board vacancies that occur between annual shareholder meetings;

· reviewing the organizational structure of the Board and its committees and succession plans for members of management; and

· overseeing the evaluation processes of the Board and its committees.

All of the Compliance and Governance Committee members meet the independence requirements of the NASDAQ listing standards and the SEC.  The Compliance and Governance Committee held four meetings in 2015.

Audit Committee

The Audit Committee’s responsibilities include, among other things:

· facilitating our relationship with our independent registered public accounting firm;

· reviewing and assessing the performance of our accounting and finance personnel;

· communicating to the Board the results of work performed by and issues raised by our independent registered public accounting firm and legal counsel; and

· evaluating our management of assets and reviewing policies relating to asset management.

All of the Audit Committee members meet the independence and experience requirements of the NASDAQ listing standards and the SEC.  The Board has identified Richard Nigon as an audit committee financial expert under the rules of the SEC.  The Audit Committee held four meetings in 2015.

Compensation Committee

The Compensation Committee’s responsibilities include, among other things:

· discharging the responsibilities of the Board of Directors with respect to the compensation of our executive officers and non-employee directors;

· setting performance goals and objectives for the Chief Executive Officer and the other executive officers;

· evaluating the performance of the Chief Executive Officer and the other executive officers with respect to goals; and

· setting the compensation of the Chief Executive Officer and the other executive officers based upon the evaluation of their performance.

In evaluating executive officer pay, the Compensation Committee considers recommendations from our Chief Executive Officer and Vice President of Human Resources with respect to the goals and compensation of the executive officers.  The Compensation Committee assesses the information it receives in accordance with its business judgment.  All decisions with respect to executive officer compensation are reviewed by the Board of Directors and approved by the Compensation Committee.

All of the Compensation Committee members meet the independence requirements of the NASDAQ listing standards and the SEC.  In addition, each Compensation Committee member is a “non-employee” director, as defined in the Exchange Act, and is an “outside director” as defined in Section 162(m) of the Internal Revenue Code.  The Compensation Committee held two meetings during 2015.

8

Director Selection and Qualifications

The Board of Directors determines the slate of director nominees for election by shareholders based on recommendations by the Compliance and Governance Committee.  All director nominees approved by the Board and all individuals appointed to fill vacancies created between our annual meetings of shareholders are required to stand for election by our shareholders at the next annual meeting.

The Compliance and Governance Committee determines the required selection criteria and qualifications of director nominees based upon the needs of Vascular Solutions at the time nominees are considered.  A candidate must possess the ability to apply good business judgment and must be in a position to properly exercise his or her duties of loyalty and care.  Candidates should also exhibit proven leadership capabilities, high integrity and experience with a high level of responsibilities within their chosen fields, and have the ability to quickly grasp complex principles of business, finance, international transactions and medical technologies.  In general, candidates will be preferred who hold an established executive level position in the medical field, finance, law, education, research or government.  The Compliance and Governance Committee will consider these criteria for nominees identified by the Board, by shareholders, or through some other source.  When current Board members are considered for nomination for re-election, the Compliance and Governance Committee also takes into consideration their prior Board contributions, performance and meeting attendance records.

The Compliance and Governance Committee will consider qualified candidates for possible nomination that are recommended by our shareholders.  Shareholders wishing to make such a recommendation may do so by sending the following information to the Board of Directors c/o Corporate Secretary, Vascular Solutions, Inc., 6464 Sycamore Court North, Minneapolis, MN 55369:  (1) name of the candidate and a brief biographical sketch and resume; (2) contact information for the candidate and a document evidencing the candidate’s willingness to serve as a director if elected; and (3) a signed statement as to the submitting shareholder’s current status as a shareholder and the number of shares currently held.

The Compliance and Governance Committee conducts a process of making an assessment of each proposed nominee based upon the resume and biographical information, an indication of the individual’s willingness to serve and other information.  The Compliance and Governance Committee considers diversity of professional experience, areas of expertise relevant to our operations and demographic diversity as factors when identifying director nominees, but the Compliance and Governance Committee does not have a specific policy with regard to the consideration of diversity.  On the basis of information learned during the assessment process, the Compliance and Governance Committee determines which nominees to recommend to the Board to submit for election at the next annual meeting.  The Compliance and Governance Committee uses the same process for evaluating all nominees, regardless of the original source of the nomination.

No candidates for director nominations were recommended to the Compliance and Governance Committee by any shareholder in connection with the 2016 annual meeting.  Any shareholder desiring to recommend a director candidate for consideration by the Compliance and Governance Committee for our 2017 annual meeting must do so prior to November 25, 2016, in order to provide adequate time to duly consider the nominee.

Communications with the Board

We have a formal process for shareholder communications with the Board to ensure that the views of shareholders are heard by the Board or individual directors, as applicable, and that appropriate responses are provided to shareholders in a timely manner.  Shareholders who wish to communicate with the Board of Directors may do so by writing to:  Vascular Solutions, Inc., Board of Directors, 6464 Sycamore Court North, Minneapolis, MN 55369.

Risk Oversight by the Board of Directors

The Board of Directors takes an active role in risk oversight related to the company and primarily administers its role during Board and Committee meetings.  During regular meetings of the Board of Directors, members of the Board discuss the operating results for each fiscal quarter with the director, vice president or senior vice president of each department.  These discussions allow the members of the Board of Directors to analyze any significant financial, operational, competitive, economic, regulatory and legal risks of our business model, as well as how effectively we implement our strategic and budgetary goals.  The independent members of the Board of Directors routinely meet without the presence of management to further discuss these topics.  If applicable, the Board of Directors will also discuss any Code of Business Ethics and Conduct issues with the Compliance Officer.

9

During regular Audit Committee meetings, Audit Committee members discuss the financial results for the most recent fiscal quarter with the independent auditors, Chief Financial Officer and Chief Executive Officer.  The Audit Committee also meets with, and provides instruction to, the independent auditors outside the presence of management.  These discussions allow the members of the Audit Committee to analyze any significant risks that could materially impact the financial health of our business.

The Compensation Committee oversees our executive compensation arrangements, including the identification and management of risks that may arise from our compensation policies and practices.  The Compensation Committee believes that the risks arising from our executive compensation programs are not reasonably likely to have a material adverse effect on Vascular Solutions.  To further mitigate the inherent risk there may be in our incentive and equity compensation programs, in 2013 the Compensation Committee recommended, and the Board of Directors adopted, an Executive Compensation Recoupment Policy.  The policy requires our officers to enter into an Executive Compensation Recoupment Agreement to receive incentive compensation or equity incentive awards after January 1, 2014.  The agreement provides for us to recoup incentive compensation or equity awards based on a financial statement restatement or corporate or individual misconduct, as identified in the agreement.  The form of the agreement was filed as an exhibit to our Annual Report on Form 10-K for the year ended December 31, 2013.

The Compliance and Governance Committee oversees risks associated with compliance with our Code of Conduct, federal healthcare program and other legal requirements.  The Compliance and Governance Committee also oversees the risks associated with succession planning and corporate governance practices.

DIRECTOR COMPENSATION

To determine how appropriate the current level of compensation for our non-employee directors is, we have historically obtained data from a number of different sources including:

· publicly available data for the companies in the Compensation Peer Group (as defined in “Overview of Compensation and Process” below);

· survey data collected by our human resources department; and

· information obtained directly from other companies.

The Compensation Committee is responsible for making recommendations to the Board of Directors regarding changes to the compensation of non-employee directors, and the Board of Directors approves any changes to non-employee director compensation.  The current compensation of non-employee directors was established by the Board of Directors effective as of July 1, 2012.  In 2013, the Compensation Committee engaged Grant Thornton LLP to conduct an analysis of our non-employee director compensation for 2014.  Grant Thornton evaluated our non-employee director compensation program compared to the non-employee director compensation for the companies in our Compensation Peer Group at that time.  The Compensation Committee reviewed the Grant Thornton analysis in December 2013 and made no change to the compensation of non-employee directors.  The Compensation Committee again reviewed the compensation of non-employee directors in each of November of 2014 and December of 2015, without engaging a compensation consultant, and made no change in the director compensation program.

Set forth below are schedules of the cash fees paid to our non-employee directors, other than the Chairman of the Board, as of the end of 2015. In lieu of these cash fees, the Chairman of the Board is paid a monthly cash retainer of $10,000.

10

Annual Retainers			($)
Board Members				20,000
Audit Committee:
Chair				10,000
Members				3,000
Compensation Committee:
Chair				8,000
Members				1,000
Compliance and Governance Committee:
Chair				4,000
Members				1,000
Meeting Fees	In Person ($)		Telephonic ($)
Board		2,000		500
Audit Committee:
Chair		1,000		500
Members		500		500
Compensation Committee:
Chair		1,000		1,000
Members		1,000		500
Compliance and Governance Committee:
Chair		1,000		1,000
Members		500		500

Each of our non-employee directors receives a restricted share award each year with a fair market value of $75,000 on the date of his or her initial election or re-election to the Board of Directors at the annual meeting of shareholders.  The number of shares subject to the award is determined based on the closing share price on the date of the annual shareholder meeting.  The shares subject to the award vest fully on the first anniversary of the date of grant, with accelerated vesting upon a change of control.  We also reimburse directors for out-of-pocket expenses incurred in attending Board meetings and necessary business expenses.

Directors who are also our employees do not receive cash or equity compensation for services on the Board of Directors in addition to compensation payable for their services as an employee of Vascular Solutions.

2015 Director Compensation

Name	Fees Earned or Paid in Cash ($)		Stock and Option Awards ($)(1)(2)		Total ($)
John Erb		120,000		75,000		195,000
Richard Nigon		44,500		75,000		119,500
Jorge Saucedo		41,000		75,000		116,000
Paul O’Connell		38,500		75,000		113,500
Martin Emerson		36,000		75,000		111,000
Richard Kramp		35,000		75,000		110,000

(1) These amounts are calculated based on the aggregate grant date fair value computed in accordance with ASC Topic 718.  The assumptions used to determine this grant date fair value can be found in Footnote 2 of our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2015.  At the May 1, 2015 Board of Directors meeting, each non-employee director was granted a restricted stock award of 2,298 shares, which vests 100% upon the one-year anniversary of the date of grant.  The grant date fair value of this non-employee director restricted stock award grant was determined based on a $32.63 per share fair market value on the grant date, May 1, 2015.  Each non-employee director owned 2,298 unvested restricted stock awards at December 31, 2015.

11

(2) Prior to 2013, our non-employee director compensation included the grant of an option to purchase 10,000 shares of our common stock on the date of each non-employee director’s initial election or re-election to the Board of Directors.  From these options grants, our non-employee directors held the following number of stock options at December 31, 2015:  John Erb, 30,000 options; Martin Emerson, 30,000 options; Richard Nigon, 70,000 options; and Jorge Saucedo, 40,000 options.

RELATED PERSON TRANSACTION POLICY AND RELATED PERSON TRANSACTIONS

Related Person Transaction Policy

Our Code of Business Ethics and Conduct (the “Code”) provides that our Compliance Officer and the Chair of our Audit Committee are responsible for monitoring and reviewing all matters involving potential conflicts of interest, which include related person transactions.  The Code also provides that the prior approval of the Board of Directors or our Compliance Officer is required with respect to any such conflict of interest.  Effective December 5, 2014, the Board of Directors appointed our Vice President of Compliance as the Compliance Officer.  While serving in this capacity, the Compliance Officer reports directly to the Board of Directors.  All directors, officers, and employees are required to read the Code and acknowledge a compliance certificate.

Under the Code, our directors, officers, and employees are required to report, in person or in writing, any conflict of interest or related party transaction to either the Compliance Officer or the Chair of the Audit Committee.  Our Compliance Officer is authorized to investigate and determine an appropriate response for all matters arising under the Code, including conflicts of interest and related party transactions.

In addition to the Code, in 2008 we adopted a written policy and procedures regarding transactions with related persons (“Related Party Policy”), which we amended in 2009.  The Related Party Policy addresses our policies, procedures, and standards for review or ratification of any transaction with a related party required to be reported in our filings with the SEC (“Covered Transaction”).  Pursuant to the Related Party Policy, the members of the Audit Committee are responsible for reviewing and approving Covered Transactions, using such processes and information that they deem reasonable in light of the circumstances to determine if the Covered Transaction is fair and reasonable and on terms no less favorable than could be obtained in a comparable arm’s length transaction with an unrelated party.

Related Person Transactions

Matthew Nigon, the adult son of Richard Nigon, a member of our Board of Directors and the Chair of the Audit Committee, is employed by Vascular Solutions as an Account Manager.  He earned aggregate compensation during 2015 of $167,000.  His employment was approved in accordance with the Related Party Policy.

Other than as disclosed above, during 2015, we did not participate in any transaction in which a related party had a direct or indirect material interest that was required to be disclosed under the rules of the SEC.

EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

We are committed to attracting, hiring and retaining an experienced management team that can successfully manufacture and sell our existing medical devices and develop new products.  The Compensation Committee believes that the most effective compensation program is one that is designed to reward the achievement of specific annual, long-term and strategic goals by the company, and which aligns executives’ interests with those of the shareholders by rewarding performance above established goals, with the ultimate objective of improving shareholder value.  The Compensation Committee evaluates both performance and compensation to ensure that we maintain our ability to attract and retain superior employees in key positions and that compensation provided to key employees remains competitive relative to the compensation paid to similarly situated executives of our peer companies.  Accordingly, the Compensation Committee believes executive compensation packages provided to our executives should include both cash and stock-based compensation that reward performance as measured against established goals.

12

At our 2014 annual meeting of shareholders, we provided our shareholders with the opportunity to cast an advisory vote on the compensation of the named executive officers as described in the 2014 proxy statement.  Over 95% of shares voting on the proposal were voted in favor of approval of the compensation of the named executive officers.  The Compensation Committee believes that this was an overall endorsement by the shareholders of our approach to executive compensation. At our 2017 annual meeting of shareholders, we will provide our shareholders with another opportunity to cast an advisory vote on the compensation paid to the named executive officers as described in the proxy statement related to that meeting.  In addition, we will provide our shareholders with the opportunity to cast an advisory vote on the frequency with which we would hold such say-on-pay votes. The Compensation Committee will take into account the outcomes of the 2017 votes when making compensation decisions for the named executive officers in the future.

Overview of Compensation and Process

The Compensation Committee has worked with management to design the current executive compensation programs, following the belief that compensation should reflect the value created for the shareholders while furthering our strategic goals.  In doing so, we instituted our compensation programs to achieve the following goals:

· align the interests of management with those of shareholders;

· provide fair and competitive compensation;

· integrate compensation with our business plans;

· reward both business and individual performance; and

· attract and retain key executives that are critical to our success.

These objectives emphasize pay for performance by providing an incentive opportunity for at or above targeted performance.  The compensation package for each executive officer is comprised of three elements:  (i) base salary, which reflects individual performance and is designed primarily to be competitive with salary levels in the industry; (ii) bonus payments contingent upon achievement of specific corporate and individual objectives; and (iii) long-term stock-based incentive awards, which strengthen the mutuality of interests between the executive officers and our shareholders.  To provide employees with flexibility in their mix of cash and non-cash compensation, in 2015 the Compensation Committee allowed all employees, including executive officers, who received awards in the annual restricted stock award grant to make an election to receive one-third of the amount awarded in 2015 in cash, rather than in shares of our common stock.  If cash payments were elected, one-half of the cash election (one-sixth of the total award) was paid in November 2015 and the other one-half (again, one-sixth of the total award) will be paid in April 2016, subject to continued employment.  The cash payment option will not be offered related to 2016 restricted stock awards.  Except for bonus potential determined under the Executive Incentive Compensation Plan described below, and the cash election related to 2015 restricted stock awards, there is no pre-established formula or target for the allocation between either cash and non-cash or short-term and long-term incentive compensation.

In 2013, the Board of Directors adopted an Executive Compensation Recoupment Policy.  The policy requires our officers to enter into an Executive Compensation Recoupment Agreement to receive incentive compensation or equity incentive awards after January 1, 2014.  The agreement provides for us to recoup incentive compensation or equity awards based on a financial statement restatement or corporate or individual misconduct, as identified in the agreement.  The form of the agreement was filed as an exhibit to our Annual Report on Form 10-K for the year ended December 31, 2013.  The agreements do not apply to any incentive compensation for periods prior to, or equity awards granted prior to, January 1, 2014.

13

Our Vice President of Human Resources administers our compensation program.  The Vice President of Human Resources prepares an annual report, with the input from our Chief Executive Officer, on executive compensation, which is provided to the Compensation Committee for use in determining executive compensation.  For most of our history, the report was prepared without the use of an independent compensation consultant.  In 2013, the Compensation Committee engaged Grant Thornton LLP to conduct a market analysis of executive compensation, which was included in the annual report on executive compensation for 2014.  The Compensation Committee did not engage an independent compensation consultant in determining executive officer compensation for 2015.  In 2015, the Compensation Committee engaged Compensia consultants as an independent compensation consultant to review the structure of our executive compensation program and provide information that was included in the annual report on executive compensation for 2016.  That report was used by the Compensation Committee in determining executive compensation for 2016, which will be disclosed in the proxy statement for our 2017 annual meeting of shareholders.

The annual report on executive compensation for 2015 (the “Report”) contained recommendations for compensation of the executive officers named in the Summary Compensation Table in this proxy statement (the “named executive officers”).  The Report included information from two compensation surveys.  The first survey, conducted by our Human Resources department, contained SEC proxy statement filings of the publicly held medical device companies most comparable to us, which consisted of the following companies (the “Compensation Peer Group”):

Abiomed, Inc.	DexCom, Inc.	Spectranetics Corporation
AngioDynamics, Inc.	Endologix, Inc.	STAAR Surgical Company
AtriCure, Inc.	ICU Medical, Inc.	Synergetics USA, Inc.
Atrion Corporation	LeMaitre Vascular Inc.	Tornier N.V.
Cardiovascular Systems, Inc.	Medical Action Industries Inc.	TriVascular Technologies, Inc.
CryoLife, Inc.	Merit Medical Systems, Inc.	Volcano Corporation
Cutera, Inc.	Natus Medical Incorporated

The Compensation Peer Group, which is consistent with peer groups previously used by the Compensation Committee in evaluating executive compensation, updated for companies that have been acquired, consists of companies the Compensation Committee believes are comparable to us in terms of revenue, number of employees, complexity of the business and company performance.

The second survey from which data was included in the Report was conducted by Mercer LLC and entitled the 2014 Mercer SIRS Executive Survey (the “Mercer Report”).  We did not benchmark against a specific company in the Mercer Report, but rather utilized the data from the Mercer Report as a general guide to market compensation levels in the medical device industry.

The Report and performance evaluations presented by management were used by the Compensation Committee to determine base salaries for 2015, to determine incentive compensation under the Executive Incentive Compensation Plan, and to review previously granted stock awards and recommendations for future awards.  In determining executive compensation, the Compensation Committee considered our quantitative performance results and our overall need to attract, retain and motivate the executive team.

Determining the Chief Executive Officer’s Compensation

The Compensation Committee approves the Chief Executive Officer’s total compensation package.  The Compensation Committee meets in executive session (without the Chief Executive Officer present) to approve the Chief Executive Officer’s base pay, annual incentive compensation and stock-based compensation, and generally bases its approval upon:

· an evaluation of total compensation paid to chief executive officers in the Compensation Peer Group;

· an evaluation of the Chief Executive Officer’s performance for the fiscal year conducted by the Compensation Committee;

· an evaluation of the proposed total compensation of the Chief Executive Officer in comparison to the other executive officers; and

· a comparison of the differential of total compensation paid to chief executive officers and executive officers in the Compensation Peer Group.

14

The evaluation is also based upon the Chief Executive Officer’s success in achieving his performance objectives, which include financial, strategic and company culture/leadership goals.

Determining Compensation for the Named Executive Officers (Other than the Chief Executive Officer)

The Compensation Committee approves the total compensation (including salary, annual incentive compensation, and stock-based compensation) for the named executive officers other than the Chief Executive Officer based upon:

· the executive’s scope of responsibilities;

· market competitive assessment of similar roles within the Compensation Peer Group;

· internal comparisons to the compensation of other executives, including the Chief Executive Officer;

· oral evaluations of performance for the fiscal year, as submitted by the Chief Executive Officer; and

· the Chief Executive Officer’s recommendations for each of the other named executive officer’s base pay, annual incentive compensation and stock-based compensation amounts.

Base Salaries

In addition to reviewing the salaries paid to executive officers in the Compensation Peer Group, the Compensation Committee analyzes each named executive officer’s individual performance during the prior year, our overall performance during the prior year, and historical compensation levels within the executive officer group in determining base salaries.  Salaries are further based on experience level and time in the position, and are intended to be competitive with salaries paid to comparable executives in similar positions at other medical device companies within the Compensation Peer Group.  The Compensation Committee believes executive salaries must be sufficient to attract and retain key individuals.  The Compensation Committee does not use a set formula in determining base salaries nor does it set salaries based upon a certain percentage or range of salaries as compared to those executives in the Compensation Peer Group.  It is our policy not to pay our named executive officers at the highest salary level relative to the officer’s peers but rather to set his or her compensation on the basis of achieving corporate and individual goals, the value of the position within the company, the value that individual brings to the position, and historical compensation levels within our executive officer group.

For fiscal 2015, the named executive officers had base salary increases ranging from approximately 4.8% to 16.7%.  The Compensation Committee approved the following base salaries for each of the named executive officers for the fiscal years ended 2015 and 2014:

Name	2015 Base Salary				2014 Base Salary		Percentage Increase
Howard Root	$	550,000			$	525,000		4.8	%
James Hennen	$	300,000			$	280,000		7.1	%
Charmaine Sutton	$	383,333	(1	)	$	360,000		6.7	%
Chad Kugler	$	350,000			$	300,000		16.7	%
Carrie Powers	$	300,000			$	265,000		13.2	%

(1) In 2015, Ms. Sutton’s annual base salary was $400,000 from January through August, while she served as Senior Vice President of Operations, and $350,000 from September through December, while she served as Senior Vice President, Regulatory & Quality Assurance.

Incentive Bonus Awards

The Compensation Committee is responsible for the administration of our Executive Incentive Compensation Plan, which was initially established by the Compensation Committee in 2000.  The purpose of the Executive Incentive Compensation Plan is to provide executive officers with the opportunity to earn annual incentive bonus awards that are commensurate with our financial performance and the executive officer’s individual contributions to that performance, and that are competitive with companies in the Compensation Peer Group.

15

Under the Executive Incentive Compensation Plan, the Chief Executive Officer can earn a bonus of 50% of his base salary and Senior Vice Presidents can earn a bonus of 30% of their base salaries for achieving a target level of performance against corporate and individual objectives.  The Chief Executive Officer’s bonus is weighted 75% on corporate objectives and 25% on individual objectives and Senior Vice Presidents’ bonuses are weighted 60% on corporate objectives and 40% on individual objectives.

At the beginning of each year, certain corporate and individual performance goals are set.  The corporate objectives are initially proposed by our Chief Executive Officer.  The Compensation Committee then reviews, revises and approves the corporate objectives.  The individual performance objectives are initially proposed by each named executive officer in consultation with the Chief Executive Officer.  The Compensation Committee then reviews, revises and approves the individual performance objectives.  The Compensation Committee assigns a target performance level for attainment of each corporate and individual objective, as well as a threshold performance level below 100% of the target level for any individual or corporate objective, and then determines an appropriate payout percentage for both scenarios.  The Compensation Committee may or may not include a performance level above 100% attainment of the corporate or individual objectives, and may also reserve the discretion to subjectively analyze any achievement in excess of an individual or corporate objective.  Under the Executive Incentive Compensation Plan, there is no guaranteed minimum payout, which means the minimum level of payout for any objective or all the objectives is zero.

At the end of the fiscal year, the Compensation Committee determines overall individual achievement for each named executive officer by taking the achievement percentage for each individual objective, multiplying the achievement percentage by the weight given to each individual objective, and then totaling the individual objective percentages to obtain the overall percentage of individual objectives achieved.

As necessary, the Compensation Committee may modify or re-weigh the corporate objectives and/or individual objectives during the course of the fiscal year to reflect changes in our business plan.  The Compensation Committee did not modify or re-weigh the corporate objectives in 2015 and no individual objective was modified in 2015.  Based upon results achieved, the named executive officers receive bonus awards in accordance with the following standards.

2015 Vascular Solutions Corporate Objectives

The following table outlines the 2015 corporate objectives set under the Executive Incentive Compensation Plan as well as the relative weightings assigned to each objective.

Vascular Solutions Corporate Objectives	Weight of Objective
(1) Achieve $141 million in net revenue in 2015		30	%
(2) Attain 2015 adjusted earnings per share of $0.90		30	%
(3) Achieve specific milestones for five material new products		20	%
(4) Acquire or enter into an agreement to distribute a material new product		20	%

For the first objective, we had to obtain revenue of at least $139 million for any payout, at which level the payout would be 50%, increasing by increments of 5% for every $200,000, up to 100% at $141 million, and then increasing by increments of 5% for every $1 million above $141 million, up to 125% at $146 million.  In 2015, we reported net revenue of $147.2 million.  The Compensation Committee, therefore, determined that a 125% payout was achieved for the first corporate objective.

For the second objective, we had to obtain adjusted earnings per share of at least $0.88, at which level the payout would be 50%, increasing by 25% for every $0.01 per share over $0.88 per share, up to 100% at adjusted earnings per share of $0.90, and then increasing by an additional 5% for every $0.01 over $0.90 per share, up to 125% at adjusted earnings per share of $0.95.  In 2015, we reported adjusted earnings of $1.04 per fully diluted share.  The Compensation Committee, therefore, determined that a 125% payout was achieved for the second corporate objective. Adjusted earnings per share was calculated as earnings per share adjusted for certain unpredictable events, as determined by the Compensation Committee.

16

For the third objective, we had to obtain at least three of five specific development milestones for planned new products, at which level the payout would be 50%, increasing by 25% each for the fourth and fifth products launched and milestones achieved.  In 2015, the development milestones were achieved for two of the planned new products, resulting in no payout for the third corporate objective.

For the fourth corporate objective, we had to acquire, complete development, or enter into a distribution agreement for selling new products or services that were projected to achieve specified revenue levels in 2016.  At the threshold revenue level, the pay-out would be 50%, increasing to the target pay-out level if projected revenue for the product was at the target level, with over-achievement potential of up to 50% if projected revenue for the product exceeded the target level.  In 2015, we entered into a distribution agreement projected to generate 2016 revenues at the objective target level, resulting in 100% payout for the fourth corporate objective.

The following table summarizes the results of Vascular Solutions 2015 corporate objectives and the Compensation Committee’s determination of the achievement of those objectives as described above.

Vascular Solutions Corporate Objectives	Weight of Objective			Achievement of Objective			Total
(1) Achieve $141 million in net revenue in 2015		30	%		125.0	%		37.50	%
(2) Attain 2015 adjusted earnings per share of $0.90		30	%		125.0	%		37.50	%
(3) Achieve specific milestones for five material new products		20	%		—	%		—	%
(4) Acquire or enter into an agreement to distribute a material new product		20	%		100.0	%		20.00	%
				Total				95.00	%

As reflected in the table above, in 2015, 95.00% of the overall weighted corporate objectives were achieved.

2015 Individual Objectives

The 2015 individual objectives established under the Executive Incentive Compensation Plan for each of the named executive officers are summarized below.  In establishing the individual objectives for 2015, the Compensation Committee reserved the right to subjectively analyze any achievement in excess of an objective and to award additional bonus compensation accordingly.

Howard Root’s individual objectives were based upon:  achieving specific development milestones for certain new products, effectively managing the short kit litigation, meeting the objectives of the 2015 Investor Relations Plan, and recruiting and hiring two net additional high potential employees.  Overall, Mr. Root met 75.00% of his weighted individual objectives.

James Hennen’s individual objectives were based upon:  effectively managing our facility renovations, meeting guidance for revenue and earnings per share, reducing annualized tax expense by developing tax saving strategies, managing outstanding receivables and limiting write-offs, and retaining, recruiting and hiring two high potential employees.  Overall, Mr. Hennen met 96.25% of his weighted individual objectives.

Charmaine Sutton’s individual objectives were based upon:  managing our facility renovations as they related to Operations and Quality, achieving specific cost savings, managing the implementation of a Quality system, recruiting and hiring two high potential employees, and managing operating expenses.  Overall, Ms. Sutton met 75.00% of her weighted individual objectives.

Chad Kugler’s individual objectives were based upon:  achieving design freeze of high priority development projects, completing a specific product defined animal study, implementing an acceptable medical advisory board, and recruiting and hiring two high potential employees.  Overall, Mr. Kugler met 38.75% of his weighted individual objectives.

17

Carrie Powers’ individual objectives were based upon:  improving the efficiency within the Training and/or Marketing Communications departments, implement four programs that increase product sales, improving the performance and/or personnel in the three functional marketing areas, managing operating expenses, and recruiting and hiring one high potential employee.  Overall, Ms. Powers met 43.75% of her weighted individual objectives.

Bonuses Awarded

At its December 2015 meeting, the Compensation Committee analyzed the percentages of achievement of the corporate and individual objectives in awarding bonuses under the Executive Incentive Compensation Plan, subject to our final year-end results.  The Compensation Committee approved the 2015 bonus awards on January 22, 2016.  For fiscal 2015, Mr. Root’s incentive bonus award consisted of $195,937 based on achievement of the corporate objectives and $51,563 based on achievement of his individual objectives.  For fiscal 2015, Mr. Hennen’s incentive bonus award consisted of $51,300 based on achievement of the corporate objectives and $34,650 based on achievement of his individual objectives.  For fiscal 2015, Ms. Sutton’s incentive bonus award consisted of $65,736 based on achievement of the corporate objectives and $34,598 based on achievement of her individual objectives.  For fiscal 2015, Mr. Kugler’s incentive bonus award consisted of $59,850 based on the achievement of the corporate objectives and $16,275 based upon achievement of his individual objectives.  For fiscal 2015, Ms. Powers’ incentive bonus award consisted of $35,625 based on the achievement of the corporate objectives and $16,406 based upon achievement of his individual objectives.  The following table summarizes the total bonus award for each named executive officer in 2015:

Name	Potential Bonus as a Percentage of Salary (1)			Corporate Level of Achievement of Objectives in 2015 (%)		Individual Level of Achievement of Objectives in 2015 (%)		Bonus Earned (%)		Bonus Awarded ($)
Howard Root		50.00	(2)		95.00		75.00		90.00		247,500
James Hennen		30.00	(3)		95.00		96.25		95.50		85,950
Charmaine Sutton		30.00	(3)		95.00		75.00		87.00		100,334
Chad Kugler		30.00	(3)		95.00		38.75		72.50		76,125
Carrie Powers		30.00	(3)		95.00		43.75		69.38		52,031

(1) At the target level performance on all corporate and individual objectives.

(2) Weighted 75% on corporate objectives and 25% on individual objectives.

(3) Weighted 60% on corporate objectives and 40% on individual objectives.

Long-Term Incentives

Long-term incentives are provided to the named executive officers through the grant of restricted stock.  Our general policy is to grant restricted stock to executives at the first Board of Directors meeting of the year.  The grants are designed to align the interest of each executive officer with those of our shareholders and provide each executive officer with an incentive to manage our business from the perspective of an owner with an equity stake in the business.  In general, we view the grants as incentives for future performance and not as compensation for past accomplishments.  While there is no set formula that we use in granting restricted stock to executive officers, the Compensation Committee takes into consideration the job responsibilities, experience and contributions of the individual, time in the position, as well as the recommendations of our Chief Executive Officer, in determining the amount (if any) of restricted stock to award to executive officers.  The Compensation Committee also considers stock awards made by companies in the Compensation Peer Group and awards made to our other executive officers.

In 2015, the Compensation Committee reviewed and recommended to the Board of Directors for approval a dollar value for restricted stock awards to the named executive officers.  To provide employees with flexibility in their mix of cash and non-cash compensation, the Compensation Committee allowed all employees, including the named executive officers, who received awards in the 2015 annual restricted stock award grant to make an election to receive one-third of the amount to be awarded in cash, rather than in shares of common stock.  If cash payments were elected, one-half of the cash election (one-sixth of the total award) was paid in November 2015 and the other one-half (again, one-sixth of the total award) will be paid in April 2016, subject to continued employment.  The amount of the cash election paid in November 2015 to the named executive officers is disclosed under the “Bonus” column of the Summary Compensation Table below.  The Board of Directors approved the following restricted stock awards, net of cash elections, on January 30, 2015 as a reflection of each executive’s performance and the impact of the executive’s knowledge, skills and abilities to meet the corporation’s strategic objectives.

18

Name	2015 Restricted Stock Award
Howard Root		18,341
James Hennen		7,336
Charmaine Sutton		9,170
Chad Kugler		6,725
Carrie Powers		7,336

The restricted stock award vests 50% at the two-year anniversary of the date of the grant, 25% at the third-year anniversary of the date of the grant, and 25% at the fourth-year anniversary of the date of the grant.  Vesting of restricted stock awards is conditioned on continued employment with Vascular Solutions.  In the event that an executive officer’s employment is terminated for any reason (other than change of control), including death or disability, prior to vesting, all of the executive officer’s rights to all of the unvested shares shall be immediately and irrevocably forfeited.

Payments upon Change of Control

Named executive officers are eligible for change of control payments under two separate compensation arrangements.  First, upon becoming an executive officer, each executive officer signs an employment agreement that provides for certain benefits if the executive officer’s employment is terminated within 12 months following a “change in control” as defined in the agreement, unless such termination was by us for cause, by the officer other than for “good reason,” or because of the officer’s disability or death.  The Compensation Committee believes these benefits will eliminate or reduce any reluctance our executive officers may have to pursue potential change of control transactions that may be in the best interest of shareholders.  These employment agreements with executives provide for a “double trigger”, which means that there must be a change of control and either a termination of the employee by us, or a termination by the employee after a certain set of criteria defined as “good cause” are met, before the executive officer is entitled to any payment under the agreement.  The Compensation Committee believes this prevents unnecessary payments to executive officers during a friendly (non-hostile) takeover where the executive’s employment is not terminated or if the employee voluntarily leaves without “good cause” as defined in the employment agreement.

Second, the Restricted Stock Award Agreements received by employees in connection with each restricted stock award, the Restricted Stock and Cash Election Award Agreements received by employees who made restricted stock cash elections in 2015, and the Incentive Stock Option Agreement received by Mr. Root in connection with a 2012 stock option grant contain a change of control provision that modifies the vesting and payment schedule in the award such that all unvested shares vest, and all unpaid cash payments under the restricted stock cash election are paid, upon a “change in control” as defined in the agreements.  These agreements provide for a “single trigger,” which means that a change of control alone triggers the vesting of any unvested restricted stock and stock options and the payment of unpaid cash payments under the restricted stock cash election.  The Compensation Committee believes that a “single trigger” is warranted because it removes certain restrictions on selling shares of stock already granted to the employees upon the occurrence of a change of control.  Unpaid cash payments under the restricted stock cash election are paid upon a change of control so that they receive the same treatment as restricted stock shares.  This “single trigger” does not impact the number of shares an employee has the ability to vote upon a change of control so long as he or she remains an employee because employees are granted voting rights in 100% of the shares underlying a grant of restricted stock on the grant date.  The stock options must be exercised within 30 days of the date of the “change of control” otherwise they expire.

19

Internal Revenue Code Section 162(m)

As a result of Section 162(m) of the Internal Revenue Code of 1986, as amended, we are not allowed a federal income tax deduction for compensation paid to certain executive officers to the extent that compensation exceeds $1 million per officer in any one year.  This limitation applies to all compensation paid to the covered executive officers that is not considered to be performance-based.  Compensation that does qualify as being performance-based is excluded from this limitation.  The Compensation Committee believes that options granted under our Stock Option and Stock Award Plan meet the requirements for qualifying as performance-based compensation.

Restricted stock awards that vest based only on the passage of time and continued employment of the executive do not qualify as performance-based compensation under Section 162(m) and are included in the executive officer’s compensation at market value at the time they vest, unless the executive made an election to treat the award as income when it was granted.  At the 2014 meeting of shareholders, our shareholders approved the Vascular Solutions, Inc. 2014 Qualified Performance-Based Compensation Plan (the “Qualified Plan”).  The Qualified Plan allows cash or stock-based awards granted after its adoption and subject to its provisions to qualify as performance-based compensation, excluded from the 162(m) limitation.  The Compensation Committee may choose to provide for compensation that is not deductible by us under Section 162(m) in order to meet its compensation objectives.

Compensation Committee Report

The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis with management.  Based upon this review and discussion, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

Compensation Committee of the Board of Directors:

John Erb, Chairman

Martin Emerson

Jorge Saucedo

20

Summary Compensation Table

The following table shows compensation for the last three fiscal years for the individuals who served as Chief Executive Officer and Chief Financial Officer during 2015 and each of the other three most highly compensated executive officers who were serving as executive officers at the end of 2015.

Name and Principal Position	Year	Salary ($)				Bonus ($)(1)		Stock and Option Awards ($)(2)				Non-Equity Incentive Plan Compensation ($)(3)		All Other Compensation ($)(4)		Total ($)
Howard Root	2015		550,000				―		499,976				247,500		―		1,297,476
Chief Executive Officer	2014		525,000				―		499,990				142,980		―		1,167,970
	2013		500,000				―		443,963				190,625		―		1,134,588
James Hennen	2015		300,000				50,000		199,979				85,950		4,500		640,429
Senior Vice President of	2014		280,000				―		199,996				39,228		4,375		523,599
Finance and Chief Financial Officer	2013		265,000				―		181,681				61,533		3,188		511,402
Charmaine Sutton	2015		383,333	(5	)		62,500		249,974				100,334		4,500		800,641
Senior Vice President,	2014		360,000				―		249,995				61,992		4,380		676,367
Regulatory & QA	2013		340,000				―		221,982				70,839		3,188		636,009
Chad Kugler	2015		350,000				45,833		183,324				76,125		4,066		659,348
Senior Vice President of	2014		196,000	(6	)		―		999,995	(7	)		40,982		2,631		1,239,608
Research & Development
Carrie Powers	2015		300,000				50,000		199,979				52,031		3,470		605,480
Vice President of	2014		265,000				―		149,997				40,827		3,384		459,208
Marketing	2013		250,000				―		150,001				44,141		1,690		445,832

(1) Represents cash payments under the 2015 restricted stock cash election, pursuant to which employees who received restricted stock awards in 2015 were allowed to make an election to receive one-third of the amount awarded in cash, rather than in shares.  If cash payments were elected, one-half of the cash election (one-sixth of the total award) was paid in November 2015 and the other one-half will be paid in April 2016, subject to continued employment on the payment date.

(2) The amounts in this column are calculated based on the aggregate grant date fair value computed in accordance with ASC Topic 718.  The assumptions used to determine this grant date fair value can be found in Footnote 2 of our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2015.  The grant date fair value of the 2015 Stock and Option Awards was determined based on a $27.26 per share fair market value on the grant date, January 30, 2015.  The grant date fair value of the 2014 Stock and Option Awards was determined based on a $23.54 per share fair market value on the grant date, January 31, 2014, except as otherwise noted.  The grant date fair value of the 2013 Stock and Option Awards was determined based on a $16.26 per share fair market value on the grant date, February 1, 2013.

(3) Represents bonuses earned under our Executive Incentive Compensation Plan as described under the “Incentive Bonus Awards” section in the Compensation Discussion and Analysis.

(4) Amounts shown for each executive officer represent the matching contributions made to the 401(k) savings plan on behalf of the executive officer.

(5) Ms. Sutton’s annual base salary was $400,000 from January through August of 2015, while she served as Senior Vice President of Operations, and $350,000 from September through December 2015, while she served as Senior Vice President, Regulatory & Quality Assurance.

(6) Mr. Kugler was hired on March 10, 2014 on a part-time basis until July 1, 2014, when he commenced full time employment.

(7) The grant date fair value of Mr. Kugler’s 2014 Stock and Option Awards was determined based on a $26.75 per share fair market value on the grant date, March 10, 2014.

21

Grants of Plan-Based Awards for Fiscal 2015

The following table summarizes the 2015 grants of equity and non-equity plan-based awards to the executive officers named in the Summary Compensation Table.

Estimated Future Payouts Under Non-Equity Incentive Plan Awards(1)

All Other Stock Awards: Number of

Grant Date Fair Value of Stock

Name

Grant Date

Threshold ($)

Target ($)

Maximum ($)

Shares of Stock or Units (#)(2)

and Option Awards ($)(3)

Howard Root

―

128,906

275,000

―

―

―

1/30/15

―

―

―

18,341

499,976

James Hennen

―

45,000

90,000

―

―

―

1/30/15

―

―

―

7,336

199,979

Charmaine Sutton

―

58,817

115,000

―

―

―

1/30/15

―

―

―

9,170

249,995

Chad Kugler

―

46,725

105,000

―

―

―

1/30/15

―

―

―

6,725

183,324

Carrie Powers

―

39,375

90,000

―

―

―

1/30/15

―

―

―

7,336

199,979

(1) Under the Executive Incentive Compensation Plan, executive officers are eligible for a bonus based on the achievement of specified corporate and individual objectives as described under the “Incentive Bonus Awards” section in the Compensation Discussion and Analysis.  The Compensation Committee does not assign an overall minimum threshold or target that an executive officer must achieve in order to receive any payout at all.  Instead, the percentage of achievement for each individual goal is added to create an overall percentage of individual objectives achieved.  A similar calculation is done for the corporate objectives.  Under the Executive Incentive Compensation Plan, there are no guaranteed minimum payouts, and therefore the minimum level of potential payout is zero.  The amounts listed in the threshold column assume that the threshold level of performance was achieved with respect to each corporate and individual objective.  The amounts listed in the target column assume that the target level of performance was achieved with respect to each corporate and individual objective.  There are no amounts listed in the maximum column because the amounts of payments under the Executive Incentive Compensation Plan for achievements in excess of objectives were at the discretion of the Compensation Committee.  The actual awards made to the executive officers are reported in the Non-Equity Incentive Plan Compensation column in the Summary Compensation Table and are discussed further under the “Incentive Bonus Awards” section in the Compensation Discussion and Analysis.

(2) The amounts included under this column represent restricted stock awarded under the Stock Option and Stock Award Plan.  Each restricted stock award vests 50% at the two-year anniversary of the date of the grant, 25% at the third-year anniversary of the date of the grant, and 25% at the fourth-year anniversary of the date of grant.  Vesting of the restricted stock awards is conditioned on continued employment with Vascular Solutions.  In the event that an executive officer’s employment is terminated for any reason (other than a change of control), including death or disability, prior to vesting, all of the executive officer’s rights to all of the unvested shares will be immediately and irrevocably forfeited.  Holders of restricted stock have the right to receive dividends on the shares of restricted stock held by them.

(3) The amounts included under this column reflect the grant date fair value of the restricted stock awards.  They are calculated based on the aggregate grant date fair value computed in accordance with ASC Topic 718.  The assumptions used to determine this grant date fair value can be found in Footnote 2 of our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2015.

22

Outstanding Equity Awards at 2015 Fiscal Year-End

The following table summarizes the unexercised stock options and unvested restricted stock held at the end of fiscal year 2015 by the executive officers named in the Summary Compensation Table.

Option Awards

Stock Awards

Name

Option Grant Date

Number of Securities Underlying Unexercised Options (#) Exercisable

Number of Securities Underlying Unexercised Options (#) Unexercisable

Option Exercise Price ($)

Option Expiration Date

Stock Award Grant Date(1)

Number of Shares or Units of Stock That Have Not Vested (#)

Market Value of Shares or Units of Stock That Have Not Vested ($)(2)

Howard Root

1/27/2012

90,000

―

11.03

1/27/2022

―

―

―

1/27/2012

90,000

―

12.03

1/27/2022

―

―

―

1/27/2012

90,000

―

13.03

1/27/2022

―

―

―

1/27/2012

―

90,000

14.03

1/27/2022

―

―

―

1/27/2012

―

90,000

15.03

1/27/2022

―

―

―

―

―

―

―

―

1/27/2012

9,250

318,108

―

―

―

―

―

2/1/2013

13,652

469,492

―

―

―

―

―

1/31/2014

21,240

730,444

―

―

―

―

―

1/30/2015

18,341

630,747

James Hennen

―

―

―

―

―

1/27/2012

3,750

128,963

―

―

―

―

―

2/1/2013

5,802

199,531

―

―

―

―

―

1/31/2014

8,496

292,177

―

―

―

―

―

1/30/2015

7,336

252,285

Charmaine Sutton

―

―

―

―

―

1/27/2012

3,750

128,963

―

―

―

―

―

2/1/2013

6,826

234,746

―

―

―

―

―

1/31/2014

10,620

365,222

―

―

―

―

―

1/30/2015

9,170

315,356

Chad Kugler

―

―

―

―

―

3/10/2014

37,383

1,285,601

―

―

―

―

―

1/30/2015

6,725

231,273

Carrie Powers

―

―

―

―

―

1/27/2012

3,000

103,170

―

―

―

―

―

2/1/2013

5,119

176,042

―

―

―

―

―

1/31/2014

6,372

219,133

―

―

―

―

―

1/30/2015

7,336

252,285

(1) Each restricted stock award vests 50% at the two-year anniversary of the date of grant, 25% at the third-year anniversary of the date of the grant, and 25% at the fourth-year anniversary of the date of grant, with the exception of the restricted stock award to Mr. Kugler on March 10, 2014.  The March 10, 2014 restricted stock award to Mr. Kugler vests 20% at the five-year anniversary of the date of the grant, and thereafter at 20% on each anniversary of the date of the grant over the next four years.

(2) “Market Value” has been determined based on the last sale price of our common stock ($34.39) as reported on the NASDAQ Global Select Market on December 31, 2015, the last business day of the year, multiplied by the number of shares that have not vested.

23

Option Exercises and Stock Vested for Fiscal 2015

The following table summarizes information with respect to stock option awards exercised and shares of restricted stock that vested during fiscal 2015.

	Option Awards				Stock Awards
Name	Number of Shares Acquired on Exercise (#)		Value Realized on Exercise ($)		Number of Shares Acquired on Vesting (#)		Value Realized on Vesting ($)(1)
Howard Root		―		―		31,652		880,061
James Hennen		―		―		13,302		369,625
Charmaine Sutton		―		―		15,576		431,789
Chad Kugler		―		―		―		―
Carrie Powers		―		―		10,620		295,041

(1) Value determined by multiplying the number of shares of restricted stock vested by the fair market value of our common stock on the date of vesting.

Employment Agreements, Separation Agreements, Termination and Potential Change in Control Payments

We have entered into employment agreements with each of the named executive officers.  The employment agreements provide for employment “at will,” which may be terminated by either party for any reason upon ten business days’ prior written notice.  The base salary and bonus for each of the named executive officers are determined by the Compensation Committee of our Board of Directors.  During the term of his or her employment agreement and for a period of one year after its termination, each named executive officer is prohibited from competing with us individually or in any entity whose business is directly competitive with our business.

The employment agreements provide for the payment of certain benefits to the named executive officers if their employment terminates following a “change in control.” The agreements provide for benefits if an officer’s employment is terminated within 12 months following a change in control, unless such termination was by us for cause, by the officer other than for “good reason,” or because of the officer’s disability or death.  “Good reason” is defined as the termination of employment as a result of either a diminution in the officer’s responsibilities, a reduction in salary or benefits, or a relocation of our office of more than 50 miles.  A “change in control” is generally defined as an acquisition of more than 50% of our outstanding common stock by any person or group, the merger, sale or dissolution of Vascular Solutions or the replacement of a majority of our Board of Directors with directors not recommended by the existing Board of Directors.  The agreements provide for lump sum payments or payments periodically in accordance with our normal payroll practices in effect from time-to-time following termination in amounts equal to 24 times monthly base salary in the case of Mr. Root and 12 times monthly base salary for the other named executive officers.  Mr. Root’s employment agreement, which was entered into in January 2012, also provides for payments to be made to Mr. Root equal to 12 times his monthly base salary in the event that we terminate Mr. Root’s employment at any time without cause (as defined in the agreement).

We also may grant our named executive officers options to purchase stock or shares of restricted stock pursuant to the Vascular Solutions, Inc. Stock Option and Stock Award Plan.  Pursuant to the Restricted Stock Award Agreement or Restricted Stock and Cash Election Agreement used for restricted stock grants and the Incentive Stock Option Agreement used for stock option awards, all options or shares granted and restricted stock cash elections made will vest or be paid upon a “change in control,” which has a definition similar to the definition in the employment agreement above, with an additional criteria that the majority of the existing members of the Board of Directors may make the determination that a change of control has occurred in their discretion.

Pursuant to our Executive Incentive Compensation Plan, a plan participant, whose employment has terminated and who is not an active employee on the date an annual bonus is paid, will not receive that bonus.  Notwithstanding the foregoing, the plan provides that if a participant’s employment is terminated prior to the date an annual bonus is paid due to the participant’s retirement, extended disability, or death, such participant will be eligible to receive a prorated bonus award directly or through a beneficiary, as applicable.  The prorated bonus is determined by multiplying the annual bonus award which would have been earned in a full year by the fraction of the number of days of service during the year.

24

The following table shows the potential payments upon certain termination events, retirement, death or a “change of control” of the company on December 31, 2015 for each of our named executive officers.

Name	Type of Payment	Payments Upon Voluntary Termination, Retirement, For Cause Termination, or Death on 12/31/15 ($)		Any Change of Control 12/31/15 ($)		Termination by the Company without Cause or Voluntary Termination by the Employee for Good Reason after a Change in Control on 12/31/15 ($)
Howard Root
	Cash Severance(1)		―		―		1,100,000
	Accelerated Bonus Payment(2)		247,500		―		―
	Accelerated Stock Options(3)		―		3,574,800		3,574,800
	Accelerated Restricted Stock Awards(4)		―		2,148,790		2,148,790
	Accrued Benefits(6)		52,885		―		52,885
	Total		300,385		5,723,590		6,876,475
James Hennen
	Cash Severance(1)		―		―		300,000
	Accelerated Bonus Payment(2)		85,950		―		―
	Accelerated Restricted Stock Awards(4)		―		872,956		872,956
	Accelerated Restricted Stock Cash Election(5)		―		50,000		50,000
	Accrued Benefits(6)		7,700		―		7,700
	Total		93,650		922,956		1,230,656
Charmaine Sutton
	Cash Severance(1)		―		―		384,000
	Accelerated Bonus Payment(2)		100,334		―		―
	Accelerated Restricted Stock Awards(4)		―		1,044,287		1,044,287
	Accelerated Restricted Stock Cash Election(5)		―		62,500		62,500
	Accrued Benefits(6)		27,882		―		27,882
	Total		128,216		1,044,287		1,456,169
Chad Kugler
	Cash Severance(1)		―		―		350,000
	Accelerated Bonus Payment(2)		76,125		―		―
	Accelerated Restricted Stock Awards(4)		―		1,516,874		1,516,874
	Accelerated Restricted Stock Cash Election(5)		―		43,833		43,833
	Accrued Benefits(6)		6,775		―		6,775
	Total		82,900		1,560,707		1,917,482

25

Name	Type of Payment	Payments Upon Voluntary Termination, Retirement, For Cause Termination, or Death on 12/31/15 ($)	Any Change of Control 12/31/15 ($)	Termination by the Company without Cause or Voluntary Termination by the Employee for Good Reason after a Change in Control on 12/31/15 ($)
Carrie Powers
	Cash Severance(1)	―	―	300,000
	Accelerated Bonus Payment(2)	52,031	―	―
	Accelerated Restricted Stock Awards(4)	―	750,631	750,631
	Accelerated Restricted Stock Cash Election(5)	―	50,000	50,000
	Accrued Benefits(6)	23,690	―	23,690
	Total	75,721	800,631	1,124,321

(1) Payment based on fiscal year 2015 salary, with the exception of Mr. Root where the payment is based on two times his fiscal year 2015 salary.

(2) Represents the amount earned under our Executive Incentive Compensation Plan based on fiscal 2015 performance assuming that the executive officer’s employment terminated on December 31, 2015 due to the executive officer’s retirement, extended disability or death.

(3) The valuation of these stock options was calculated by multiplying the number of unvested stock options available with an exercise price less than fair market value by the fair market value of the stock at December 31, 2015 ($34.39), less the exercise price to be paid.

(4) The valuation of these restricted stock awards was calculated by multiplying the number of restricted stock awards available by the fair market value of the stock at December 31, 2015 ($34.39).

(5) Represents the 2015 restricted stock cash election subject to accelerated payment upon a change of control.  If cash payments were elected related to the 2015 restricted stock grant, one-half of the cash election (one-sixth of the total award) will be paid in April 2016, subject to acceleration upon a change of control.

(6) The Accrued Benefits amount represents accrued vacation.  The accrued vacation amount was determined by taking the executive officer’s yearly base salary and dividing that amount by 2,080 hours using a standard 40 hour per week work year.  This hourly salary rate was then multiplied by the hours of vacation the executive officers’ had available to them at December 31, 2015.

26

REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS

The Audit Committee of our Board of Directors is composed of the following non-employee directors:  Richard Nigon, Paul O’Connell and Jorge Saucedo.  Mr. Nigon currently serves as the Chairman of the Audit Committee.  All of the members of the Audit Committee are independent for purposes of the NASDAQ Stock Market LLC listing requirements and the rules of the SEC.  The Audit Committee recommends to the Board of Directors, and submits for shareholder ratification, the appointment of our independent registered public accounting firm.

Management is responsible for our internal controls and the financial reporting process.  Our independent registered public accounting firm is responsible for performing an independent audit of our consolidated financial statements in accordance with generally accepted auditing standards and issuing a report on our financial statements.  The Audit Committee’s responsibility is to monitor and oversee these processes.

In this context, management has represented to the Audit Committee that our consolidated financial statements were prepared in accordance with generally accepted accounting principles, and the Audit Committee has reviewed and discussed the consolidated financial statements with management and our independent registered public accounting firm.  The Audit Committee discussed with our independent registered public accounting firm matters required to be discussed by the Auditing Standard No. 16.

Our independent registered public accounting firm also provided to the Audit Committee the written disclosures and the letter required by applicable requirements of the Public Company Accounting Oversight Board regarding the independent registered public accounting firm’s communications with the Audit Committee concerning independence, and the Audit Committee discussed with the independent registered public accounting firm the firm’s independence.

Based on the reviews and discussions described above, the Audit Committee recommended to the Board of Directors that the audited consolidated financial statements be included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed with the SEC.

Members of the Audit Committee:

Richard Nigon, Chairman

Paul O’Connell

Jorge Saucedo

27

PROPOSAL 2:

RATIFICATION OF APPOINTMENT OF

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

While we are not required to do so, we are submitting the appointment of Baker Tilly Virchow Krause, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2016 for ratification in order to ascertain the views of our shareholders on this appointment.  If the appointment is not ratified by the shareholders, the Audit Committee will reconsider its selection.  It is not, however, obligated to appoint another independent registered public accounting firm.

Representatives of Baker Tilly Virchow Krause, LLP are expected to be present at the annual meeting of shareholders and will have an opportunity to make a statement if they desire to do so and will be available to respond to appropriate questions from shareholders.

OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE PROPOSAL TO RATIFY THE APPOINTMENT OF BAKER TILLY AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.

The affirmative vote of a majority of the shares of our common stock present and entitled to vote at the 2016 annual meeting of shareholders is necessary to ratify the appointment of Baker Tilly Virchow Krause, LLP.  Proxies will be voted FOR ratifying the appointment unless otherwise specified.

ADDITIONAL INFORMATION ABOUT OUR INDEPENDENT REGISTERED

PUBLIC ACCOUNTING FIRM

Audit Fees

Fees billed or expected to be billed to us for audit services by Baker Tilly Virchow Krause, LLP for the audit of our annual financial statements and for reviews of our financial statements included in our quarterly reports on Form 10-Q for the fiscal years ended December 31, 2015 and 2014 were $188,500 and $176,500, respectively.

Audit-Related Fees

Fees billed or expected to be billed to us by Baker Tilly Virchow Krause, LLP for audit-related services provided for both fiscal years ended December 31, 2015 and 2014 were $0.

Tax Fees

Fees billed or are expected to be billed to us by Baker Tilly Virchow Krause, LLP for tax compliance, tax advice and tax planning for the fiscal years ended December 31, 2015 or 2014 were $54,325 and $10,700, respectively.

All Other Fees

No fees were billed or are expected to be billed to us by Baker Tilly Virchow Krause, LLP for other services not included above during the fiscal years ended December 31, 2015 or 2014.

Pre-Approval Policies and Procedures

The Audit Committee has adopted a policy that requires advance approval of all audit, audit-related, tax, and other services performed by our independent registered public accounting firm.  The policy provides for pre-approval by the Audit Committee of specifically defined audit and non-audit services.  Unless the specific service has been previously pre-approved with respect to that year, the Audit Committee must approve the permitted service before the independent registered public accounting firm is engaged to perform it.  The Audit Committee has delegated to the Chair of the Audit Committee authority to approve permitted services, provided that the Chair reports any decisions to the Audit Committee at its next scheduled meeting.  All of the services performed by our independent registered public accounting firm during 2015 and 2014 were pre-approved by the Audit Committee.

28

ANNUAL REPORT ON FORM 10-K

Our 2015 Annual Report, including our Annual Report on Form 10-K for the year ended December 31, 2015, accompanies this proxy statement.  The 2015 Annual Report, including our Form 10-K, is also available on our website at www.vasc.com.  If requested, we will provide copies of any exhibits to the Form 10-K to you upon payment of a fee covering our reasonable expenses incurred in furnishing the exhibits.  You can request exhibits to the Form 10-K, by writing to the Corporate Secretary, Vascular Solutions, Inc., 6464 Sycamore Court North, Minneapolis, Minnesota 55369.

“HOUSEHOLDING” OF PROXY MATERIALS

The SEC rules allow a single copy of the proxy statement and annual report to be delivered to multiple shareholders sharing the same address and last name, or who we reasonably believe are members of the same family, and who consent to receive a single copy of these materials in a manner provided by these rules.  This practice is referred to as “householding” and can result in significant savings of paper and mailing costs.  Although we do not household for our registered shareholders, some brokers household Vascular Solutions proxy statements and annual reports, delivering a single copy of each to multiple shareholders sharing an address unless contrary instructions have been received from the affected shareholders.  Once you have received notice from your broker that they will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent.  If, at any time, you no longer wish to participate in householding and would prefer to receive a separate copy of our proxy statement or annual report, or if you are receiving multiple copies of either document and wish to receive only one, please notify your broker.  We will deliver promptly upon written or oral request a separate copy of our proxy statement and/or our annual report to a shareholder at a shared address to which a single copy of either document was delivered.  For copies of either or both documents, shareholders should write to Vascular Solutions, Inc., 6464 Sycamore Court North, Minneapolis, Minnesota 55369, Attention:  Corporate Secretary, or call (763) 656-4300.

OTHER MATTERS

As of this date, the Board of Directors does not know of any business to be brought before the annual meeting of shareholders other than as specified above.  However, if any matters properly come before the meeting, it is the intention of the persons named in the enclosed proxy to vote such proxy in accordance with their judgment on such matters.

PROPOSALS FOR THE NEXT ANNUAL MEETING

Any shareholder proposals to be considered for inclusion in our proxy material for the 2017 annual meeting of shareholders must be received at our principal executive office at 6464 Sycamore Court North, Minneapolis, Minnesota 55369, no later than November 25, 2016.  In connection with any matter to be proposed by a shareholder at the 2017 annual meeting, but not proposed for inclusion in our proxy material, the proxy holders designated by us for that meeting may exercise their discretionary voting authority with respect to that shareholder proposal if appropriate notice of that proposal is not received by us at our principal executive office by February 8, 2017.

By Order of the Board of Directors

Gordon Weber

Secretary

Dated:  March 25, 2016

29

Shareowner Services P.O. Box 64945 St. Paul, MN 55164-0945

 

The Board of Directors Recommends a Vote FOR Items 1 and 2.

1.Electionof	01  MartinEmerson	04RichardNigon	06HowardRoot	oVoteFORall nominees	oVoteWITHHELD
directors:	02  John Erb	05 Paul O’Connell	07 Jorge Saucedo	(except as marked)	from all nominees
	03  Richard Kramp

(Instructions: To withhold authority to vote for any indicated nominee, write the number(s) of the nominee(s) in the box provided to the right.)

2.	To ratify the selection of Baker Tilly Virchow Krause, LLP as independent auditor of the Company for the year ending December 31, 2016.	o  For	o  Against	o  Abstain
3.	To transact such other business as may properly come before the meeting or any adjournment thereof.

THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, WILL BE VOTED AS THE BOARD RECOMMENDS.

Address Change? Mark box, sign, and indicate changes below: o Date

Signature(s) in Box

Please sign exactly as your name(s) appears on Proxy. If held in joint tenancy, all persons should sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the Proxy.

ANNUAL MEETING OF SHAREHOLDERS

Friday, April 29, 2016

1:30 p.m.

Crowne Plaza Minneapolis West

3131 Campus Drive

Plymouth, MN 55441

    Vascular Solutions, Inc. 6464 Sycamore Court North Minneapolis, MN 55369         Proxy

This proxy is solicited by the Board of Directors for use at the Annual Meeting on April 29, 2016.

The shares of stock you hold will be voted as you specify on the reverse side.

If no choice is specified, the proxy will be voted “FOR” Items 1 and 2.

By signing the proxy, you revoke all prior proxies and appoint Howard Root and Gordon Weber, and each of them, with full power of substitution, to vote your shares on the matters shown on the reverse side and any other matters which may come before the Annual Meeting and all adjournments.